{"id":"W4283692377","doi":"10.1177/13524585221102584","title":"Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial","year":2022,"lang":"en","type":"article","venue":"Multiple Sclerosis Journal","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; NeuroRx Research (Canada)","funders":"Innosuisse - Schweizerische Agentur für Innovationsförderung; EMD Serono; Multiple Sclerosis International Federation; Allergan; Shionogi; National Research Foundation; Janssen Pharmaceuticals; Atara Biotherapeutics; European Committee for Treatment and Research in Multiple Sclerosis; Bristol-Myers Squibb; CSL Behring; Biogen; Celgene; Alexion Pharmaceuticals; Teva Pharmaceutical Industries; Mylan; TG Therapeutics; Pfizer; Bayer HealthCare; European Commission; Sanofi; MedDay Pharmaceuticals; National Multiple Sclerosis Society","keywords":"Medicine; Adverse effect; Internal medicine; Tolerability; Pediatrics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006613942,0.0006772178,0.001922264,0.0002435326,0.000735371,0.001019087,0.0006037243,0.001359973,0.003152262],"category_scores_gemma":[0.00456321,0.0003118841,0.001671086,0.0003704249,0.0005315132,0.001279851,0.000701749,0.00196663,0.0005508407],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004438205,"about_ca_system_score_gemma":0.000603701,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003865578,"about_ca_topic_score_gemma":0.000802719,"domain_scores_codex":[0.99861,0.0006870447,0.0001091349,0.0002194633,0.0001651405,0.000209116],"domain_scores_gemma":[0.9952381,0.0009115053,0.001874226,0.0004658165,0.0004683176,0.001042144],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8828722,0.004499572,0.06435481,0.0007001976,0.002687813,0.0002096502,0.0002653462,0.0005936507,0.002993009,0.00009904431,0.002145091,0.03857963],"study_design_scores_gemma":[0.274043,0.2288934,0.4803762,0.0002752865,0.004680645,0.0008186186,0.0002818077,0.001871066,0.00218718,0.0005736771,0.005892525,0.0001066452],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957178,0.001755422,0.0001526485,0.0001574405,0.00005403864,0.000340722,0.001115498,0.0000165686,0.0006898229],"genre_scores_gemma":[0.9955652,0.0006118346,0.0002594677,0.0002009739,0.00009001732,0.000432607,0.002184058,0.000005913337,0.0006499159],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006613942,"threshold_uncertainty_score":0.03497827,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1887642141103295,"score_gpt":0.3523233674991694,"score_spread":0.1635591533888399,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}